You are viewing the site in preview mode

Skip to main content

Articles

Page 6 of 83

  1. Oral squamous cell carcinoma (OSCC) accounts for around 90% of all oral cancers and is the eighth most common cancer worldwide. Despite progress in managing OSCC, the overall prognosis remains poor, with a sur...

    Authors: Ishita Gupta, Fariba Badrzadeh, Yuri Tsentalovich and Daria A. Gaykalova
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:239
  2. Neoadjuvant therapy improves recurrence-free survival (RFS) in resectable stage III cutaneous melanoma. However, accurately predicting individual recurrence risk remains a significant challenge. We investigate...

    Authors: Wei Yen Chan, Jenny H. Lee, Ashleigh Stewart, Russell J. Diefenbach, Maria Gonzalez, Alexander M. Menzies, Christian Blank, Richard A. Scolyer, Georgina V. Long and Helen Rizos
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:238
  3. Anti-HER2 therapies, including the HER2 antibody–drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have led to improved survival outcomes in patients with HER2-overexpres...

    Authors: Jangsoon Lee, Kumiko Kida, Jiwon Koh, Huey Liu, Ganiraju C. Manyam, Young Jin Gi, Dileep R. Rampa, Asha S. Multani, Jing Wang, Gitanjali Jayachandran, Dae-Won Lee, James M. Reuben, Aysegul Sahin, Lei Huo, Debu Tripathy, Seock-Ah Im…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:236
  4. Ubiquitin-specific protease 15 (USP15) exhibits amplifications in various tumors, including gastric cancer (GC), yet its biological function and mechanisms in GC progression remain elusive.

    Authors: Longtao Huangfu, Huanbo Zhu, Gangjian Wang, Junbing Chen, Yongqi Wang, Biao Fan, Xiaoyang Wang, Qian Yao, Ting Guo, Jing Han, Ying Hu, Hong Du, Xiaomei Li, Jiafu Ji and Xiaofang Xing
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:235
  5. Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer-related deaths worldwide, with a survival rate near to 10% when diagnosed at an advanced stage. Hence, the...

    Authors: Valentina Piastra, Federica Ganci, Andrea Sacconi, Angelina Pranteda, Matteo Allegretti, Roberta Bernardini, Martina Serra, Barbara Lupo, Emanuela Dell’Aquila, Gianluigi Ferretti, Edoardo Pescarmona, Armando Bartolazzi, Giovanni Blandino, Livio Trusolino and Gianluca Bossi
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:234
  6. Betel quid and its major ingredient, areca nut, are recognized by IARC as major risk factors in oral cancer development. Areca nut extract (ANE) exposure has been linked to OPMD progression and malignant trans...

    Authors: Shyng-Shiou F. Yuan, Leong-Perng Chan, Hieu D. H. Nguyen, Chang-Wei Su, Yuk-Kwan Chen, Jeff Yi-Fu Chen, Shigetaka Shimodaira, Stephen Chu‐Sung Hu, Steven Lo and Yen-Yun Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:233
  7. Tumor recurrence and mortality rates remain challenging in cancer patients despite comprehensive treatment. Neoadjuvant chemotherapy and immunotherapy aim to eliminate residual tumor cells, reducing the risk o...

    Authors: Yaoyao Zhou, Ziyun Liu, Cheng Gong, Jie Zhang, Jing Zhao, Xia Zhang, Xiangyu Liu, Bin Li, Rui Li, Zhenyu Shi, Yongjie Xie and Li Bao
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:232
  8. Glioblastoma (GB) is recognized as one of the most aggressive brain tumors, with a median survival of 14.6 months. However, there are still some patients whose survival time was greater than 3 years, and the b...

    Authors: Jizhen Li, Lingling Zhao, Zerui Wu, Shirui Huang, Junyu Wang, Yuanyuan Chang, Li Liu, Honglei Jin, Jianglong Lu, Chuanshu Huang, Qipeng Xie, Haishan Huang and Zhipeng Su
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:231
  9. tRNA-derived small RNAs (tsRNAs) are newly discovered non-coding RNA, which are generated from tRNAs and are reported to participate in several biological processes in diseases, especially cancer; however, the...

    Authors: Rong Xu, Ashuai Du, Xinpei Deng, Wei Du, Kaiying Zhang, Jianbo Li, Yingxue Lu, Xiaoli Wei, Qinglong Yang and Hailin Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:230
  10. Authors: Kai Liu, Minying Zheng, Qi Zhao, Kexin Zhang, Zugui Li, Fangmei Fu, Hao Zhang, Jiaxing Du, Yuwei Li and Shiwu Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:229

    The original article was published in Journal of Experimental & Clinical Cancer Research 2020 39:83

  11. The failure of proper recognition of the intricate nature of pathophysiology in colorectal cancer (CRC) has a substantial effect on the progress of developing novel medications and targeted therapy approaches....

    Authors: Junqi Shan, Xinyu Li, Runqi Sun, Yao Yao, Yan Sun, Qin Kuang, Xianling Dai and Yanlai Sun
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:227
  12. Circulating cytokines can represent non-invasive biomarkers to improve prediction of clinical outcomes of cancer patients. Here, plasma levels of IL-8, CCL4, osteopontin, LIF and BDNF were determined at baseli...

    Authors: Lauretta Levati, Claudio Tabolacci, Antonio Facchiano, Francesco Facchiano, Ester Alvino, Gian Carlo Antonini Cappellini, Enrico Scala, Laura Bonmassar, Simona Caporali, Pedro Miguel Lacal, Antonella Bresin, Federica De Galitiis, Giandomenico Russo and Stefania D’Atri
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:226
  13. Long non-coding RNAs (LncRNAs) have been implicated as critical regulators of cancer tumorigenesis and progression. However, their functions and molecular mechanisms in colorectal cancer (CRC) still remain to ...

    Authors: Qingqing Luo, Fei Shen, Sheng Zhao, Lan Dong, Jianchang Wei, He Hu, Qing Huang, Qiang Wang, Ping Yang, Wenlong Liang, Wanglin Li, Feng He and Jie Cao
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:225
  14. High infiltration of tumor-associated macrophages (TAMs) is associated with tumor promotion and immunosuppression. The triggering receptor expressed on myeloid cells 2 (TREM2) is emerged as a key immunosuppres...

    Authors: Qiaohua Wang, Yongjian Wu, Guanmin Jiang and Xi Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:224
  15. CRISPR-Cas13a is renowned for its precise and potent RNA editing capabilities in cancer therapy. While various material systems have demonstrated efficacy in supporting CRISPR-Cas13a to execute cellular functi...

    Authors: Mingkang Liang, Yongqiang Wang, Lisha Liu, Dashi Deng, Zeqin Yan, Lida Feng, Chenfan Kong, Chenchen Li, Yuqing Li and Guangzhi Li
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:223
  16. The mechanisms enabling dynamic shifts between drug-resistant and drug-sensitive states in cancer cells are still underexplored. This study investigated the role of targeted autophagic protein degradation in r...

    Authors: Pratham Phadte, Aniketh Bishnu, Pranay Dey, Manikandan M, Megha Mehrotra, Prerna Singh, Shritama Chakrabarty, Rounak Majumdar, Bharat Rekhi, Malay Patra, Abhijit De and Pritha Ray
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:222
  17. Authors: Fei Fei, Dan Zhang, Zhengduo Yang, Shujing Wang, Xian Wang, Zhengsheng Wu, Qiang Wu and Shiwu Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:221

    The original article was published in Journal of Experimental & Clinical Cancer Research 2015 34:158

  18. Over the last decade, accumulating evidence has suggested that tumor-associated macrophages (TAMs) play a significant role in the tumor development. This commentary wishes to highlight the findings by You, et ...

    Authors: Chen-xi Li, Zhong-cheng Gong and Jing-wen Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:220

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:228

  19. In non-small cell lung cancer (NSCLC) the efficacy of chemo-immunotherapy is affected by the high expression of drug efflux transporters as ABCC1 and by the low expression of ABCA1, mediating the isopentenyl p...

    Authors: Muhlis Akman, Ciro Monteleone, Gabriella Doronzo, Martina Godel, Francesca Napoli, Alessandra Merlini, Virginia Campani, Valeria Nele, Elisa Balmas, Tatiana Chontorotzea, Simona Fontana, Sabrina Digiovanni, Francesca Alice Barbu, Elena Astanina, Niloufar Jafari, Iris Chiara Salaroglio…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:219

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:244

  20. Glioblastoma (GBM) poses a significant challenge in oncology, with median survival times barely extending beyond a year due to resistance to standard therapies like temozolomide (TMZ). This study introduces a ...

    Authors: Hsien-Chung Chen, Hong-Yi Lin, Yung-Hsiao Chiang, Wen-Bin Yang, Chung-Han Wang, Pei-Yu Yang, Siou-Lian Hu and Tsung-I Hsu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:218
  21. Aberrant alternative splicing events play a critical role in cancer biology, contributing to tumor invasion, metastasis, epithelial-mesenchymal transition, and drug resistance. Recent studies have shown that a...

    Authors: Aurora Cordaro, Maria Magdalena Barreca, Chiara Zichittella, Marco Loria, Denise Anello, Goffredo Arena, Nicolina Sciaraffa, Claudia Coronnello, Giuseppe Pizzolanti, Riccardo Alessandro and Alice Conigliaro
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:217
  22. The resistance of cancer cells to treatment significantly impedes the success of therapy, leading to the recurrence of various types of cancers. Understanding the specific mechanisms of therapy resistance may ...

    Authors: Xiaozhu Tang, Mengjie Guo, Yuanjiao Zhang, Junxian Lv, Chunyan Gu and Ye Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:216
  23. Human papilloma virus (HPV) related cancers of the oropharynx are rapidly increasing in incidence and may soon represent the majority of all head and neck cancers. Improved monitoring and surveillance methods ...

    Authors: Flaminia Campo, Oreste Iocca, Francesca Paolini, Valentina Manciocco, Silvia Moretto, Armando De Virgilio, Claudio Moretti, Antonello Vidiri, Aldo Venuti, Paolo Bossi, Giovanni Blandino and Raul Pellini
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:215
  24. Melanoma progression is based on a close interaction between cancer cells and immune cells in the tumor microenvironment (TME). Thus, a better understanding of the mechanisms controlling TME dynamics and compo...

    Authors: Alessandro Giammona, Chiara De Vellis, Enrica Crivaro, Luisa Maresca, Roberta Amoriello, Federica Ricci, Giulia Anichini, Silvia Pietrobono, David R. Pease, Martin E. Fernandez-Zapico, Clara Ballerini and Barbara Stecca
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:214
  25. Non-small cell lung cancer (NSCLC) is characterized by a high incidence rate and poor prognosis worldwide. A deeper insight into the pathogenesis of NSCLC and identification of novel therapeutic targets are es...

    Authors: Tian Yao Liu, Jin Shan Yan, Xin Li, Lu Xu, Jun Li Hao, Su Ya Zhao, Qi Lin Hu, Fang Jian Na, He Ming Li, Yue Zhao and Ming Fang Zhao
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:213
  26. Prolonged interferon-γ signaling activation induces cancer resistance to therapeutics, especially immunotherapy. However, the detailed mechanisms are not well characterized. In present study, we explored cance...

    Authors: Yunhe Han, Cunyi Zou, Tianqi Liu, Wen Cheng, Peng Cheng and Anhua Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:212
  27. Early cutaneous squamous cell carcinomas (cSCCs) generally show epithelial differentiation features and good prognosis, whereas advanced cSCCs present mesenchymal traits associated with tumor relapse, metastas...

    Authors: Marta Lopez-Cerda, Laura Lorenzo-Sanz, Victoria da Silva-Diz, Sandra Llop, Rosa M. Penin, Josep Oriol Bermejo, Richard de Goeij-de Haas, Sander R. Piersma, Thang V. Pham, Connie R. Jimenez, Juan Martin-Liberal and Purificación Muñoz
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:211
  28. It has been proposed that anti-angiogenesis therapy could induce tumor "vascular normalization" and further enhance the efficacy of chemotherapy, radiotherapy, target therapy, and immunotherapy for nearly twen...

    Authors: Ying Chen, Zhiyong Zhang, Fan Pan, Pengfei Li, Weiping Yao, Yuxi Chen, Lei Xiong, Tingting Wang, Yan Li and Guichun Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:210
  29. Immune cell-derived extracellular vesicles (EV) affect tumor progression and hold promise for therapeutic applications. Eosinophils are major effectors in Th2-related pathologies recently implied in cancer. He...

    Authors: Adriana Rosa Gambardella, Caterina Antonucci, Cristiana Zanetti, Francesco Noto, Sara Andreone, Davide Vacca, Valentina Pellerito, Chiara Sicignano, Giuseppe Parrottino, Valentina Tirelli, Antonella Tinari, Mario Falchi, Adele De Ninno, Luca Businaro, Stefania Loffredo, Gilda Varricchi…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:209
  30. Colorectal cancer (CRC) metachronous liver metastasis is a significant clinical challenge, largely attributable to the late detection and the intricate molecular mechanisms that remain poorly understood. This ...

    Authors: Yixun Zhang, Yumeng Yang, Xuan Qi, Peng Cui, Yi Kang, Haiyi Liu, Zhigang Wei and Haibo Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:208
  31. Targeted delivery and precise release of toxins is a prospective strategy for the treatment of triple-negative breast cancer (TNBC), yet the flexibility to incorporate both properties simultaneously remains tr...

    Authors: Yao Chen, Jirui Yang, Chuanqi Wang, Tianbao Wang, Yingjie Zeng, Xiao Li, Yi Zuo, Hongyu Chen, Chaozheng Zhang, Yuening Cao, Chen Sun, Maolin Wang, Xiujun Cao, Xian Ge, Yilan Liu, Ge Zhang…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:207
  32. The escalating prevalence of metabolic diseases has led to a rapid increase in non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (NASH-HCC). While oxaliplatin (OXA)-based hepatic arterial i...

    Authors: Zhu Lin, Zhenkun Huang, Jiliang Qiu, Yunxing Shi, Dinglan Zuo, Zhiyu Qiu, Wei He, Yi Niu, Yunfei Yuan and Binkui Li
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:206
  33. Despite the use of targeted therapeutic approaches, T-cell acute lymphoblastic leukemia (T-ALL) is still associated with a high incidence of complications and a poor prognosis. Indisulam (also known as E7070),...

    Authors: Tongting Ji, Yang Yang, Juanjuan Yu, Hongli Yin, Xinran Chu, Pengju Yang, Ling Xu, Xiaodong Wang, Shaoyan Hu, Yizhen Li, Xiaochen Wu, Wengyuan Liu, Bi Zhou, Wenjuan Wang, Shuqi Zhang, Wei Cheng…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:205
  34. Endometrial cancer (EC) stem cells (ECSCs) are pivotal in the oncogenesis, metastasis, immune escape, chemoresistance, and recurrence of EC. However, the specific mechanism of stem cell maintenance in EC cells...

    Authors: Bo Wang, Yuting Wang, Wantong Wang, Zihao Wang, Yunzheng Zhang, Xin Pan, Xin Wen, Hongrui Leng, Jing Guo and Xiao-xin Ma
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:204
  35. Blacks/African American (BAA) patients diagnosed with head and neck squamous cell carcinoma (HNSCC) have worse survival outcomes than White patients. However, the mechanisms underlying racial disparities in HN...

    Authors: Fan Yang, Fanghui Chen, Chloe Shay, Georgia Z. Chen, Nabil F. Saba and Yong Teng
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:203
  36. Lung cancer remains one of the most prevalent cancer types worldwide, with a high mortality rate. Upregulation of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) may represent a key mechanism for...

    Authors: Dantong Sun, Lipin Tan, Yongbing Chen, Qiang Yuan, Kanqiu Jiang, Yangyang Liu, Yuhang Xue, Jinzhi Zhang, Xianbao Cao, Minzhao Xu, Yang Luo, Zhonghua Xu, Zhonghen Xu, Weihua Xu and Mingjing Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:202
  37. Studies have confirmed that epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC)-like properties are conducive to cancer metastasis. In recent years, testes-specific protease 50 (TSP50) has been ...

    Authors: Feng Gao, Sichen Liu, Jing Wang, Gang Wei, Chunlei Yu, Lihua Zheng, Luguo Sun, Guannan Wang, Ying Sun, Yongli Bao and Zhenbo Song
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:201
  38. The progression of non-small cell lung cancer (NSCLC) is significantly influenced by circular RNAs (circRNAs), especially in tumor hypoxia microenvironment. However, the precise functions and underlying mechan...

    Authors: Lixia Li, Dewei Liu, Tingting Chen, Chunhui Wei, Youping Qiao, Weiliang Liu, Yanmei Liang, Zhu Liang, Chunyuan Chen, Dongming Li, Bin Wu, Xuanna Zhao, Dan Huang and Dong Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:200
  39. Pancreatic cancer (PC) is a clinically challenging tumor to combat due to its advanced stage at diagnosis as well as its resistance to currently available therapies. The absence of early symptoms and known det...

    Authors: Carla Mottini, Francesca Romana Auciello, Isabella Manni, Christian Pilarsky, Damiano Caputo, Giulio Caracciolo, Alessandro Rossetta, Elena Di Gennaro, Alfredo Budillon, Giovanni Blandino, Maria Serena Roca and Giulia Piaggio
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:198
  40. Plasmacytoid dendritic cells (pDCs) are multifaceted immune cells executing various innate immunological functions. Their first line of defence consists in type I interferons (I-IFN) production upon nucleic ac...

    Authors: Matilde Monti, Giorgia Ferrari, Luisa Gazzurelli, Mattia Bugatti, Fabio Facchetti and William Vermi
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:196
  41. Metastasis is the major cause of colorectal cancer (CRC) mortality. Emerging evidence suggests that long noncoding RNAs (lncRNAs) drive cancer metastasis and that their regulatory pathways could be targeted fo...

    Authors: Yunze Liu, Heng Lv, Xin Liu, Lei Xu, Tiankang Li, Hui Zhou, Hongmei Zhu, Chuanchuan Hao, Changwei Lin and Yi Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:195
  42. Continued exploration of the androgen receptor (AR) is crucial, as it plays pivotal roles in diverse diseases such as prostate cancer (PCa), serving as a significant therapeutic focus. Therefore, the Departmen...

    Authors: Justus Simon Israel, Laura-Maria Marcelin, Christian Thomas, Eva Szczyrbová, Susanne Fuessel, Martin Puhr, Johannes Linxweiler, Shivani Yalala, Wilbert T. Zwart, Aria Baniahmad, Jasper van Goubergen, Harri M. Itkonen, Adam Sharp, Edward O’Neill, Marc Pretze, Matthias Miederer…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:194
  43. Macrophages play important roles in phagocytosing tumor cells. However, tumors escape macrophage phagocytosis in part through the expression of anti-phagocytic signals, most commonly CD47. In Ewing sarcoma (ES...

    Authors: Wen Luo, Hai Hoang, Katherine E. Miller, Hongwen Zhu, Serena Xu, Xiaokui Mo, Elizabeth A. R. Garfinkle, Heather Costello, Saranga Wijeratne, Wiebke Chemnitz, Ronan Gandhi, Yanling Liao, Janet Ayello, Aliza Gardenswartz, Jeremy M. Rosenblum, Kevin A. Cassady…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:193
  44. Treatment with regorafenib, a multiple-kinase inhibitor, to manage metastatic colorectal cancers (mCRCs) shows a modest improvement in overall survival but is associated with severe toxicities. Thus, to reduce...

    Authors: Prachi Bajpai, Sumit Agarwal, Farrukh Afaq, Sameer Al Diffalha, Darshan S. Chandrashekar, Hyung-Gyoon Kim, Abigail Shelton, C. Ryan Miller, Santosh K. Singh, Rajesh Singh, Sooryanarayana Varambally, Ganji Purnachandra Nagaraju, Ashish Manne, Ravi Paluri, Moh’d Khushman and Upender Manne
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:192
  45. The potential involvement of circular RNAs (circRNAs) and N6-methyladenosine (m6A) modification in the progression of Wilms tumor (WT) has not been fully elucidated. This study investigates the regulatory mechani...

    Authors: Guannan Shu, Zhang Zhao, Tianxin Zhao, Changmi Deng, Jiangquan Zhu, Yufeng Han, Minyu Chen, Jiajia Jing, Gaochen Bai, Dian Li, Feng Li, Jing He, Wen Fu and Guochang Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:191
  46. Pyroptosis is a cell death process characterized by cell swelling until membrane rupture and release of intracellular contents. As an effective tumor treatment strategy, inducing tumor cell pyroptosis has rece...

    Authors: Mengyuan Hu, Fengying Deng, Xinlei Song, Hongkun Zhao and Fei Yan
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:190
  47. Distinguishing benign from malignant pancreaticobiliary disease is challenging because of the absence of reliable biomarkers. Circulating extracellular vesicles (EVs) have emerged as functional mediators betwe...

    Authors: Daniel S.K. Liu, Jisce R. Puik, Bhavik Y. Patel, Morten T. Venø, Mahrou Vahabi, Mireia Mato Prado, Jason P. Webber, Eleanor Rees, Flora M. Upton, Kate Bennett, Catherine Blaker, Benoit Immordino, Annalisa Comandatore, Luca Morelli, Shivan Sivakumar, Rutger-Jan Swijnenburg…
    Citation: Journal of Experimental & Clinical Cancer Research 2024 43:189

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 11.4
    5-year Journal Impact Factor: 11.4
    Source Normalized Impact per Paper (SNIP): 1.770
    SCImago Journal Rank (SJR): 2.806

    Speed 2024
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 96

    Usage 2024
    Downloads: 4,059,655
    Altmetric mentions: 2,197